Ampio Pharma rises on positive data from joint disease study

Ampio Pharmaceuticals

02/03/2022 21:47

** Drug developer's shares  AMPE.A  rise 21.9% to $0.61 in
extended trading
    ** Co reports positive results from modified patient
population in a late-stage study testing intra-articular
injection Ampion in adults with pain due to severe
osteoarthritis of the knee (OAK)
    ** Complete analysis of study data show Ampion reduced pain
with statistical significance
    ** Study was designed to confirm efficacy observed in the
first pivotal trial and was powered to detect treatment
differences between Ampion and saline control
    ** OAK is a degenerative joint disease of the knee. It is
typically the result of wear and tear and progressive loss of
articular cartilage
    ** Stock has lost 11.63% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))